News

CBSA Applauds Third Annual Gold Lab Symposium

Mon, 14 May 2012 21:11:00 GMT

Colorado BioScience Association Applauds Organizers of the Third Annual
Gold Lab Symposium at the University of Colorado

Colorado BioScience Association (CBSA) applauds Dr. Larry Gold and his team at the University of Colorado for their efforts in organizing the third annual Gold Lab Symposium. The annual two-day educational event brings together ground-breaking thought leaders to discuss biological innovations and the improvement of health care.

Denver, CO, May 12, 2012 - Colorado BioScience Association (CBSA) applauds organizers of the third annual Gold Lab Symposium that will take place on the University of Colorado campus with over 400 attendees, on Friday and Saturday, May 18 - 19, 2012. The two-day event titled “Time: Tempus Fugit” brings 16 renown national and international scientists and healthcare experts together to discuss progress and issues in personalized medicine. The announcement is made by Holli Riebel, CBSA President & CEO, who says, “We are honored to assist support the Gold Lab Symposium—the speakers are incredible visionaries from an array of diverse fields. Every year I am personally inspired and amazed by the groundbreaking thought leaders Dr. Gold is able to bring together in one room.”

The Gold Lab Symposia were initiated in 2010 to bring together an intelligent community of scientists, industry leaders and policy experts to foster discussion about biological innovations and the improvement of health care. “Each year our Colorado bioscience community looks forward to the Symposium.We have some of the top research institutions in the country and 600 bioscience companies—creating the vision and drive to tackle these huge global issues,” explains Riebel.

This year the sessions will cover the expanding scientific basis of personalized medicine; explore drug targets and development, and consider the impact of education, aging, chronic conditions, and immunology on the evolution of healthcare. Presentations on healthcare economics and efficiency and reflections on the future also are included. Visit to review the 2012 itinerary: http://www.cobioscience.com/Events/Symposium_flyer2012_4-5.pdf.

“We are at a point where we must understand that healthcare and its related sciences are a huge systems problem. We now appreciate that solutions lie not only in scientific innovation and discovery, but also in political action and the transformation of healthcare delivery at both the individual and societal levels,” said Larry Gold, the Symposium’s founder.

About Gold Lab Symposium
The Symposium will be held in the Muenzinger Auditorium from 8:30 AM - 6 PM on Friday, May 18th, and 9:00AM – 6:00 PM on Saturday, May 19th. Admission is free but seats are limited. Speakers scheduled for the event are Mathias Uhlen, Jeremy Nicholson, Elvir Causevic, Glenn Treisman, Michael Teitell, Grazia Cereghetti, Alan Jacobson, Garret FitzGerald, Lloyd Fricker, James Hill, Cindy Malone, Pippa Marrack, Simon Lovestone, Jonathan Shay, William Rutter, and David Lawrence. For registration, visit: http://www.cobioscience.com/events-calendar/goldlab-symposium.

-More-
Page 2
About Colorado BioScience Association
The CBSA is a not-for-profit organization providing services and support for Colorado's bioscience industry. With more than 350 members, CBSA actively works to promote the growth of the industry by advocating for a better business environment, growing the state's biotech workforce, fighting for policies that support a strong bioscience industry in the state, and speaking with a single voice on behalf of the industry. For more information, visit http://www.cobioscience.com.

CBSA also is found on these social media sites:
Twitter: http://www.twitter.com/COBioscience
LinkedIn Group: http://www.linkedin.com/groups?about=&gid=98468&trk=anet_ug_grppro
Facebook Fan Page: http://www.facebook.com/ColoradoBioScienceAssociation
News Feed: http://coloradobio.blogspot.com
YouTube Channel: http://www.youtube.com/COBioscience
Pinterest: http://pinterest.com/COBioscience

# # #

Contacts:
Mae Desaire, Director of Marketing, Colorado BioScience Association - www.cobioscience.com – 720-382-5918, mdesaire@cobioscience.com
Maggie Chamberlin Holben, APR, Absolutely Public Relations - www.absolutelypr.com - 303-984-9801, maggie@absolutelypr.com

BCBR: Biotechs abuzz over high court ruling

Wed, 16 May 2012 17:13:00 GMT

Drug-patent decisions could affect millions in research funding
by Beth Potter

BOULDER — In the high-stakes world of drug research, local biotechnology companies are asking how recent U.S. Supreme Court rulings on drug patent issues may affect them in the future.

Millions of dollars of future funding for research could be at stake, as well as potential patent protection for existing therapeutic treatments and diagnostic tests.

The Supreme Court in March ruled that a natural process may not be patented in a case involving diagnostic test company Prometheus Laboratories Inc. in San Diego and a testing lab linked to the Mayo Clinic in Rochester, Minnesota. The testing lab had refused to pay royalties to Prometheus for the test, and the Supreme Court agreed.

Other cases related to the Prometheus case have come out of the court system since that ruling.

Several local biotechnology companies do research on a variety of gene therapies that focus on natural processes to one extent or another, according to Steven Penner, a patent attorney at Greenlee Sullivan PC in Boulder.

“Everybody needs to read the tea leaves on this,” said Penner.

At MiRagen Therapeutics Inc. in Boulder, Bill Marshall, its president, chief executive and co-founder, said the Supreme Court rulings have created “a strategic concern.”

MiRagen makes patented treatments for cardiovascular and muscle diseases. The company’s latest research is on a few particular microRNAs — research which someday could lead to effective treatments for obesity, diabetes and heart disease. MicroRNAs are small pieces of genetic material which have been found to regulate disease and stress response in various tissues of the body.

http://www.bcbr.com/article.asp?id=62992

Full story - print version

E.I. Medical Imaging Awarded ISO 9001:2008 Certification

Mon, 14 May 2012 22:38:00 GMT

LOVELAND, Colorado, E.I. Medical Imaging (EIMI), a worldwide leader in portable ultrasound systems for veterinary use announced today they have received ISO 9001:2008 Certification.

E.I. Medical Imaging (EIMI) became ISO 9001:2008 certified after successfully passing the audit of its quality management system (QMS) by Platinum Registration. The ISO 9001:2008 standards are recognized internationally and used by service and manufacturing organizations to create a standardized QMS that is continuously evaluated to ensure it conforms to the principles of quality improvement and customer satisfaction.
“This ISO 9001:2008 certification demonstrates to our customers EIMI’s strong commitment to quality throughout all levels of our organization.” said EIMI President, Charles Maloy. “It demonstrates to our customers that we are maintaining product engineering, production and customer satisfaction standards to provide the them with the best possible quality products and services.”
“This certification validates EIMI’s commitment to meeting the globally recognized International Organization for Standardization (ISO) requirements for the design and development of portable ultrasound solutions for the veterinary market,” added Maloy.
“EIMI’s overarching goal is to ingrain continuous improvement within our QMS so that we constantly improve the quality, reliability, value and integrity of our products and services,” said Maloy. “Each EIMI employee and their active participation in this system is critical to improving our products and processes for our customers per our ISO certification.”

If you have questions, feel free to contact E.I. Medical Imaging at info@eimedical.com.

Copyright© 2012 E.I. Medical Imaging. All rights reserved. All company and/or product names, trademarks and registered trademarks are the property of E.I. Medical Imaging. Features, pricing, availability, and specifications are subject to change without notice.

CONTACT
Mia Varra
Marketing Director
1.866.365.6596
mvarra@eimedical.com

Terumo BCT to Invest in State-of-the-Art Facilities in the U.S. and Vietnam

Mon, 14 May 2012 20:51:00 GMT

Terumo BCT to Invest in State-of-the-Art Facilities in the U.S. and Vietnam
Facilities expansion will help serve the growing global demand for blood and cellular therapy products

LAKEWOOD, Colo.—May 10, 2012—Terumo BCT announced plans to invest in its existing U.S. manufacturing operations at its global headquarters, based in Lakewood, Colo., and to build a new manufacturing facility in Vietnam. Investment in the Colorado and Vietnam facilities will support growth and demand for blood and cellular therapy products and equipment globally.

Key Facts:

• Terumo BCT’s parent company, Terumo Corporation, is committing $100M to fund both projects
• $6M is being leveraged to expand operations at the Colorado manufacturing facility
• Investment in the Colorado facility is planned for FY2013
• $94M is being invested in the new Vietnam facility
• Ground breaking on the new Vietnam facility is expected to begin in early 2013 with plans to have the facility complete and operational by 2015
• The Vietnam facility is being developed on an area of 10 hectares
• Terumo BCT products are manufactured in five locations: China, India, Japan, Northern Ireland and the U.S.
• Terumo BCT was established through the integration of CaridianBCT and Terumo Transfusion, following Terumo Corporation's acquisition of CaridianBCT in April 2011
• Terumo BCT, headquartered in Lakewood, Colorado, is the only Terumo Corporation subsidiary with its global headquarters located outside of Japan
• Terumo BCT has more than 2,600 associates, and customers in more than 120 countries and territories, with regional headquarters in Brussels, Buenos Aires, Hong Kong and Tokyo
• Terumo BCT serves three primary customer segments: Blood Centers, Hospitals & Therapeutic Apheresis Centers and Biotech & Cell Processing

Key Quotes:

Koji Nakao, Terumo Corporation, Chairman and Representative Director

“The investment in these facilities demonstrates our commitment to investing in Terumo BCT and to contributing to the long-term goals of the business and our mission, at Terumo, of ‘Contributing to Society through Healthcare.’”

David Perez, Terumo BCT President and CEO; Terumo Corporation, Chairman, Blood Management Business Division

“This is an exciting time for our organization. In just 12 months, we combined the businesses of CaridianBCT and Terumo Transfusion to emerge as Terumo BCT, one united global leader in blood component, therapeutic apheresis and cellular technologies.”

“With Terumo’s investment we are able to expand our global capabilities and footprint to be even more responsive to the demands of the marketplace. This investment demonstrates Terumo’s commitment to the industry, to our organization, and to better serve our current and future customers.”

Craig Rinehardt, Terumo BCT Senior Vice President, Global Operations

“The investment being made in Terumo BCT’s state-of-the-art facilities aligns our global manufacturing strategies, supports incremental capacity needs and furthers our commitment to our business continuity infrastructure. We remain focused on building the right products at the right time, while maintaining the highest level of quality and standards.”

Key Resources:

Terumo BCT About Us

About Terumo BCT:

Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction coupled with leading technologies in therapeutic apheresis and cell processing. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.

About Terumo Corporation:

Tokyo-based Terumo Corporation is one of the world's leading medical device manufacturers with operations in more than 160 nations. Founded in 1921, the company develops, manufactures and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the health care market and by responding to the needs of health care providers and the people they serve. Terumo Corporation's shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan's leading stock index.

Contact:
Laura Fusco
Global Corporate Communications
Phone: +1.303.205.2546
press@terumobct.com

Nature: Drug-making plant blooms - featuring Ventria

Tue, 08 May 2012 21:39:00 GMT

Drug-making plant blooms
Approval of a ‘biologic’ manufactured in plant cells may pave the way for similar products.
BY AMY MAXMEN

It was midnight when an anxious Ari Zimran finally got the phone call for which he had been waiting. The news couldn’t have been better: the drug he had worked on for nearly a decade had just been approved by the US Food and Drug Administration (FDA).

Zimran, who heads the Gaucher Clinic in Jerusalem and is a member of the scientific advisory board at Protalix Biotherapeutics, a small biotechnology firm in Carmiel, Israel, was not the only one celebrating the company’s success last week. Biotechnologists around the world cheered, because Protalix’s Elelyso (taliglucerase alfa) is the first biological drug for human use that is manufactured inside modified plant cells.

“It’s a great day for plant-made pharmaceuticals,” says Scott Deeter, president of Ventria Bioscience, a biotech firm based in Fort Collins, Colorado. “This shows the triumph of innovators over the status quo, and that’s really very important.”

http://www.nature.com/polopoly_fs/1.10604!/menu/main/topColumns/topLeftColumn/pdf/485160a.pdf

Clovis Oncology Announces First Quarter 2012 Operating Results

Tue, 08 May 2012 19:22:00 GMT

BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology, Inc. (NASDAQ:CLVS) today reported financial results for the first quarter 2012, and provided an update on the progress of its clinical development programs and expected milestones for the rest of the year.

I/II studies for both CO-1686 and rucaparib,” said Patrick J. Mahaffy, President and CEO of Clovis Oncology. “We continue to expect overall survival results from the LEAP study in the fourth quarter and with the completion of our follow-on offering at the beginning of April, we have sufficient funds to initiate prelaunch activities for CO-101 as well as achieve meaningful results for our other two programs.”

2012 Financial Results and Outlook

Clovis reported a net loss of $19.0 million for the first quarter of 2012. This compares to a net loss of $8.3 million for the first quarter 2011. Net loss attributable to common stockholders for the first quarter of 2012 was $0.86 per share, compared to $6.64 per share for the first quarter of 2011.

http://www.businesswire.com/news/cobioscience/20120508005645/en/Clovis-Oncology-Announces-Quarter-2012-Operating-Results

Brad Ross Named Transaction Services Partner at Hein & Associates

Mon, 14 May 2012 21:16:00 GMT

May 8, 2012 — Mr. Ross serves as Hein’s Transaction Services Leader, consulting with both corporate and private equity clients on transactions ranging from $1M to several billion dollars in deal value. Brad’s expertise extends to buy- and sell-side diligence, as well as lender services projects.

With over 20 years’ of professional experience and 13 of that dedicated to transaction services, Brad is one of the most experienced financial diligence professionals in the marketplace. He has worked on numerous high profile transactions throughout his career, including transactions in Canada, South America, Europe, India, China and Japan.

“Brad’s extensive transaction experience supports the firm’s strategic objective of offering our clients a range of world-class services to support their business goals,” explains Brian Mandell-Rice, Managing Partner.

Hein & Associates LLP is recognized as a leading audit, tax, and advisory firm serving public and private companies in a variety of industries across the country from our offices in Denver, Dallas, Houston, and Orange County. Hein also serves clients globally through its alliance with associations of independent accounting firms around the world.

###

Contact: Kimberly Daly, National Marketing Manager
Phone: (303) 298-9600
Fax: (303) 298-8118
Email: kdaly@heincpa.com

GRIFF/SMC WINS TWO GOLD KEY AWARDS

Mon, 14 May 2012 20:44:00 GMT

GRIFF/SMC WINS BEST CREATIVE, BEST STRATEGY AND TWO GOLD KEY AWARDS FROM BUSINESS MARKETING ASSOCIATION.

BOULDER, CO (May 7, 2012) – Griff/SMC, one of the nation’s leading medical marketing communications firms and Boulder, Colorado’s oldest full-service advertising agency, has been honored four times this year with the prestigious Gold Key Award from the Colorado Chapter of the Business Marketing Association (BMA). The Agency was chosen for its work on behalf of Amedica/ US Spine, a Salt Lake City based manufacturer and marketer of proprietary implants, instrumentation and biologic products used in spine surgery.

The Agency received two “Bests”, plus Gold Keys in two categories. In the Direct Marketing section, a 3-part mailing campaign entitled “Watch Technology Transform.” received a Gold Key. The program helped introduce the Tercet Pedicle Screw from Amedica/ US Spine at one of the company’s leading trade shows. The judges also awarded the entry “Best Creative” concept in the competition, as it included live ice sculptures every day of the event, as well as related campaign graphics.

In the Single Page Print Ad section, the Agency was awarded another Gold Key for its work to introduce a new line of amniotic-based tissue products used in spine surgery. With the headline: “Better outcomes are taking shape”, the judges also bestowed the honor of “Best Strategy” in the competition.

According to President and Creative Director Bob Griff, “After 37 years in the business, we find the Gold Keys to be the one awards competition that is most appreciated by our clients, since they emphasize the results of the entry. Obviously, we’re delighted to have done so well at this year’s event.”

The Gold Key Awards are recognized as Colorado’s most prestigious competition dedicated solely to business-to-business marketing communications. This year’s program had 160 entries from Colorado’s top B2B businesses and agencies.

About the Business Marketing Association
The Business Marketing Association (BMA) is a national organization that unites professionals who specialize in business-to-business marketing and communications. The Colorado Chapter has more than 550 members and one of the largest and strongest chapters in the country. The BMA Gold Key Awards is Colorado’s most prestigious competition dedicated solely to business-to-business marketing. For more information, visit www.bmacolorado.org.

###

Bob Griff
Griff/SMC, Inc.
(800) 445-7602
bgriff@griffsmc.com
www.griffsmc.com

R&D Team of Acertara Acoustic Laboratories Awarded Three New Patents

Mon, 14 May 2012 20:36:00 GMT

LONGMONT, CO May 7th, 2012. Acertara Acoustic Laboratories, the world’s only independent ISO/IEC 17025:2005 accredited medical ultrasound acoustic measurement and testing laboratory, announces that its research and development team has been awarded three new United States patents in as many weeks. US patents 8,159,900, 8,164,976, and 8,169,853, authored by John Timms, James Gessert, Matthew Fitzgibbons, and G. Wayne Moore are related to novel technology designed to validate the performance of diagnostic ultrasound systems. The R&D team members of Acertara have been awarded more than 30 United States patents.

Full release

BSW Weekly Legislative Report 5/6/2012

Mon, 07 May 2012 23:18:00 GMT

This past week resolution was reached between the health care community and the Colorado Trial Lawyers Association on their issues with HB 1300, the extension of peer review in Colorado hospitals and other faculties. HB 1361, a compromise proposal for assisting victims of the recent wildfire in Jefferson County, was introduced. Compromise was also reached on SB 174, which will create a pilot program for Denver to conduct property tax valuation appeals during the 2013 appraisal.

Bill SB12-083 - SCHEFFEL / DELGROSSO Dynamic Modeling For Fiscal Impact Of Bills
   Tuesday, May 8 2012
   GENERAL ORDERS - SECOND READING OF BILLS
   (3) in senate calendar.

Full Bill Dossier

The Innovation Center of the Rockies

Mon, 07 May 2012 23:20:00 GMT

The Innovation Center of the Rockies (formerly the Boulder Innovation Center) has entered into a commercialization partnership with CSU Ventures to accelerate the creation of new businesses based on CSU faculty research. The ICR will work with CSU Ventures staff to develop the intellectual properties holding the most promise for commercialization within a variety of markets supported by ICR including Bioscience, Cleantech, Engineering, Aerospace and IT/Software. Full story

Hein Expands NetSuite Implementation Services Team

Mon, 07 May 2012 18:42:00 GMT

May 3, 2012 — In support of its strategic partnership with cloud computing provider NetSuite and the growing demand from clients, Hein & Associates’ Business Advisory Services group has added three experienced Managers to its NetSuite Implementation Services team: Michael Dooley, Jeremy King, and Todd Lindley.

Dooley, King and Lindley have served in corporate leadership positions, providing them the unique ability to understand and predict clients’ business needs while providing optimized solutions. Michael Dooley, having served as both a Chief Financial Officer (CFO) and Controller, has extensive experience with operational improvement and internal controls, resulting in improved performance. Todd Lindley has been a Partner in a firm specializing in Software as a Service (SaaS )applications, and provides perspective on large-scale Enterprise Resource Planning (ERP) and Customer Relationship Manager (CRM) projects. Jeremy King uses his experience as a CFO and Chief Operating Officer (COO) to support clients in the areas of strategic planning, operational management and financial analysis.

“The expansion of our NetSuite Implementation Team supports Hein’s strategic objective of providing our clients a range of world-class consulting services to support their business goals,” explains Brian Mandell-Rice, Managing Partner.

Hein’s partnership with NetSuite combines a world-class online business management suite with the real-world business experience needed to maximize the investment return on a new software solution. Hein was NetSuite’s first Systems Integration Partner, has since become a NetSuite Solutions Provider.

###

Contact: Kimberly Daly, National Marketing Manager
Phone: (303) 298-9600
Email: kdaly@heincpa.com

Cochlear Americas Adds the Nucleus Support App to its Mobile Service Offerings

Mon, 07 May 2012 23:01:00 GMT

CENTENNIAL, Colo., May 2, 2012 /PRNewswire/ -- Cochlear Americas, the world's leading implantable hearing solutions company, announced today the launch of its smartphone support application for Nucleus® Cochlear Implant recipients. The Nucleus Support App joins the Baha® Support App as part of Cochlear's mobile support initiative, which provides information and assistance to recipients whenever and wherever they need it.

http://www.prnewswire.com/news-releases/cochlear-americas-adds-the-nucleus-support-app-to-its-mobile-service-offerings-149858325.html

Aurora Sentinel: Venture contest a capital idea for local bioscience start-ups looking for cash

Mon, 07 May 2012 23:15:00 GMT

By BRANDON JOHANSSON Staff Writer Aurora Sentinel | 0 comments

AURORA | It’s no secret that finding investors is one of the biggest challenges bioscience start-up companies face.

But a contest this fall is aiming to help some local start-ups land a little extra money and advice on how to make their business more enticing to investors.

The Colorado BioScience Association announced last week it is accepting nominations from emerging bioscience companies for the Venture Showcase Competition at BioWest 2012 conference this September. The deadline for nominations is May 11.

“The Venture Showcase creates a huge amount of excitement at the BioWest Conference and gives our emerging bioscience companies an opportunity to present their technologies on a large scale.

Six finalists will be chosen from the nominations and each will receive expert coaching to fine tune their presentations leading up to the conference. Finalists will have 15 minutes to pitch their technologies and business plans to a panel of bioscience experts and venture capitalists in-front of a live audience at the conference, and the winner will receive $7,500.

http://www.aurorasentinel.com/email_push/news/article_d41fe224-9393-11e1-b5d8-001a4bcf887a.html

INDUSTRY VETERAN BRINGS SALES EXPERTISE TO ALLOSOURCE

Mon, 30 Apr 2012 22:27:00 GMT

INDUSTRY VETERAN BRINGS SALES EXPERTISE TO ALLOSOURCE’S GROWING DISTRIBUTION NETWORK

CENTENNIAL, CO – April 23, 2012 – AlloSource, one of the nation’s largest non-profit providers of skin, bone and soft tissue allografts for use in surgical procedures and the world’s largest processor of cellular bone growth substitutes, announced today the hire of Dale Binke as Vice President of Sales and Marketing.

In his role as Vice President of Sales and Marketing, Dale will lead the AlloSource direct sales team and manage third-party distributors. He will also help develop company sales and marketing strategies and assist with the company’s promotional direction.

“Dale’s experience in the medical device industry makes him essential to the AlloSource team as it continues to add new distribution resources. With the sophistication of our new cellular tissue allografts, his senior leadership will help us position ourselves in the marketplace to ensure we honor the gift of donation by allowing it to help as many recipients as possible,” said Kevin Cmunt, AlloSource Executive Vice President.

Dale joins AlloSource with more than 24 years of experience in the medical device industry, including senior leadership roles with Medtronic, Orthofix, Trinity Orthopedics and Spinal Elements. In these positions, Binke managed over 80 people, multi-million dollar budgets, as well as the building and developing of strategic relationships with customers.

"I am excited to use my experience for such a passionate, mission-driven company that is truly guided by an internal compass,” said Dale. “AlloSource’s progressive innovation has the potential to help medical professionals heal many patients while also honoring the gift of donation.”

About AlloSource
AlloSource is a non-profit company that offers more than 200 types of precise bone, skin, soft-tissue and custom-machined allografts for use in an array of life-saving and life-enhancing medical procedures. As the world's leader in fresh cartilage tissue used for joint repair and skin allografts to heal severe burns, AlloSource has grown into one of the largest tissue networks in the country with more than 350 employees. It is the world’s largest processor of cellular bone growth substitutes and delivers unparalleled expertise and customer service to its growing network of surgeons, partners and the country's most reputable organ procurement organizations. As one of the leading innovators in maximizing tissue donation with the goal of offering optimal solutions for healthcare providers and their patients, AlloSource is recognized by the medical community for its ability to process and provide high quality tissue. The company is accredited by the American Association of Tissue Banks (AATB) and is headquartered in Centennial, CO. For more information, please visit our corporate website or educational website.